This disclosure is related to methods of preserving biological samples such as organs, and tissue. The present disclosure relates to methods of subzero preservation of biological tissue samples, such as entire organs from mammals, e.g., humans. The present disclosure is based, at least in part, on the discovery that biological tissue samples can be supercooled while minimizing formation of ice crystals by reducing liquid-air interfaces and lowering the melting point of the tissue samples, e.g., organs, or liquid in the tissue samples by use of cryoprotective agents while ensuring uniform distribution of cryoprotective agents throughout the biological sample by using improved perfusion techniques.

The present disclosure relates to heterogeneous cell compositions and/or heterogenous primed cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects the heterogenous cell compositions are primed with IFN-gamma. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis, chronic gingivostomatitis or wounds in canines and felines.

This disclosure is related to methods of preserving biological samples, organs. and organisms.

A temperature-responsive virus storage system that allows virus to be stored, such as a non-frozen liquid, and maintain infectivity is described.

The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0 C. to about 20 C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.

The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0 C. to about 20 C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.

The present disclosure provides, among other things, a cryopreservation medium comprising a cryoprotectant, an albumin, a disaccharide and a non-pyrogenic and isotonic crystalloid solution. The disclosure also provides, among other things, a cryopreservation medium for cryopreserving immune cells, the medium comprising: human serum albumin (HSA), sodium chloride, sodium gluconate, sodium acetate trihydrate, potassium chloride, magnesium chloride, dimethyl sulfoxide (DMSO), and a trehalose. The present disclosure also provides, a method of cryopreserving immune cells, transporting and subsequently administering such immune cells to a patient in need thereof.

Compositions and methods for cryopreservation including an amino acid at a concentration at, for example, between 50 mM and 1 M. Glutamate alone or combined with other amino acids and/or other cryoprotective molecules provides cell protection against freeze damage. Moreover, compositions and methods for cryopreservation may be provided with less or minimal toxicity by including one or more cryoprotectants at a concentration that is insufficient for crypopreservation of cells when used at that concentration alone.

Cell culture systems and methods provide improved immunotherapeutic product manufacturing with greater scalability, flexibility, and automation. Cell culture systems are configured with interchangeable cartridges, allowing versatility and scalability. Systems are configured to have multiple connected cell culture chambers, which allows parallel processing of different types of cells. Gas-impermeable cell culture chambers and methods for generating cells in closed systems prevent contamination and user error. Methods for recycling cell culture medium provide additional efficiencies.

The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.